KOL Insight

Diabetic Nephropathy, Diabetes, and Obesity KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits (including off-label) and projections for key marketed brands and late-phase pipeline therapies in diabetic nephropathy, along with information on these drugs and their competitors in the broader diabetes and obesity indications. Key assets highlighted include Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus (and other oral GLP-1 agonists), Mounjaro, Farxiga/AZD9977, Farxiga/zibotentan, and weekly insulins. The KOL also gives insight into reimbursement of Ozempic’s obesity formulation, Wegovy, in obese diabetics.